Navigation Links
Sigma-Aldrich Becomes the Sole U.S. and Canada Distributor of Kromasil(R) HPLC Columns Through Agreement With Eka Chemicals
Date:1/12/2010

ST. LOUIS, Jan. 12 /PRNewswire-FirstCall/ -- Sigma-Aldrich® (Nasdaq: SIAL) announced today it has entered a distribution agreement with Eka Chemicals to offer Eka's Kromasil® analytical HPLC columns for the separation and purification of small molecules, peptides and proteins in the pharmaceutical and biotechnology industries. This agreement includes distribution in the U.S., Canada and Puerto Rico, and expands Sigma-Aldrich's portfolio of chromatography solutions offered through its Supelco® brand. In addition to the classic Kromasil phases, the new pH stable Kromasil Eternity™ C18 and Kromasil chiral phases are now available from Sigma-Aldrich at http://www.sigma-aldrich.com/kromasil.

"Kromasil analytical columns are useful tools to serve as a high performance spherical silica media for analytical to process-scale HPLC, SFC, and SMB applications," said Wayne K. Way, Ph.D., Sigma-Aldrich HPLC Marketing Manager.  "Sigma-Aldrich is committed to being the complete chromatography solution provider, and this agreement enables us to provide more robust solutions for the research community."

Sigma-Aldrich's agreement with Eka complements Sigma-Aldrich's comprehensive collection of chromatography products that support applications in environmental testing, food and beverage analysis, air monitoring, gas chromatography, chiral chromatography and clinical industry applications.  For more information on Sigma-Aldrich chromatography solutions, visit http://www.sigma-aldrich.com/chromatography.

The foregoing release contains forward-looking statements that can be identified by terminology such as "solutions," "useful tools," "provide more robust solutions," "comprehensive," or similar expressions, or by express or implied discussions regarding Kromasil HPLC columns, or regarding potential future revenues from products derived therefrom. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that products derived from Kromasil HPLC columns will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma-Aldrich:  Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development and as key components in pharmaceutical, diagnostic and other high technology manufacturing. Sigma-Aldrich has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 38 countries and has 7,800 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Innovation and Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning website at http://www.sigma-aldrich.com.

Sigma-Aldrich and Supelco are registered trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co. Kromasil is a registered trademark of EKA Chemicals AB.

SOURCE Sigma-Aldrich

RELATED LINKS
http://www.sigma-aldrich.com

'/>"/>

SOURCE Sigma-Aldrich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sigma-Aldrich to Present at the 28th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2010
2. Sigma-Aldrich Enters Distribution Agreement With Stemgent, Inc. to Offer Lentivirus-Based Gene Delivery Products for Regenerative Medicine and Stem Cell Research
3. Sigma-Aldrich Announces SAGE(TM) Priority Partners Program; Seeks Researchers to Evaluate New Knockout Rat Models
4. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
5. Sigma-Aldrich (Nasdaq: SIAL) Announces Appointment of George Miller as Sr. Vice President, General Counsel & Secretary
6. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
7. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. CVS Caremarks MinuteClinic Becomes First Retail Clinic Provider to Achieve Consecutive Accreditation Awards From The Joint Commission
10. Hope International Centro de Radioterapia of Guatemala Becomes First in Latin America to Treat Cancer Using RapidArc(R) Radiotherapy Technology From Varian Medical Systems
11. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Eyevensys, a private biotechnology company developing its ... that enables the safe, local, sustained production of therapeutic ... of ophthalmic diseases, announces it has received approval from ... to advance its technology into clinical development. ... The EyeCET platform uses ...
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology:
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Providing for ... understand the estate planning process, or where to even begin. “Now more than ever ... you are to properly protect yourself and your family,” said attorney Lisa Edgar Dickman, ...
(Date:4/21/2017)... ... April 21, 2017 , ... Westside Dental Associates ... dental care since 1985. After thirty-two years, Dr. Latner has become one of the ... my numerous clients over the years with all their dental needs,” said Dr. Latner, ...
(Date:4/21/2017)... ... ... Each year, everyone is urged to give back to the earth on April ... a better future. However, supporting the environment should be an everyday practice. , ... to five times more polluted than outdoor air, reports the Environmental Protection Agency -- ...
(Date:4/21/2017)... Houston, Texas (PRWEB) , ... April 21, 2017 ... ... repeal…. sound familiar? These are five common elements between the Obamacare program ... feral hog control program which uses Warfarin poison to kill hogs. , ...
(Date:4/21/2017)... ... April 21, 2017 , ... Indiana ... significant bandwidth upgrade infrastructure service to Tele-Media Solutions. IFN is delivering Multi-Gigabit ... IFN’s consortium member-owners, Tele-Media Solution’s protect transport with 3GB Dual Access Internet access ...
Breaking Medicine News(10 mins):